Podcast
Questions and Answers
Topical ______ are effective to decrease inflammation and pruritus in acute and chronic forms of AD.
Topical ______ are effective to decrease inflammation and pruritus in acute and chronic forms of AD.
Corticosteroids
Wet wrap dressings have been shown to reduce ______ and pruritus by serving as a barrier to trauma, cooling the skin and improving penetration of topical therapies.
Wet wrap dressings have been shown to reduce ______ and pruritus by serving as a barrier to trauma, cooling the skin and improving penetration of topical therapies.
inflammation
For mild disease activity, small amounts of ______ in combination with liberal emollient use may be sufficient without producing adverse effects.
For mild disease activity, small amounts of ______ in combination with liberal emollient use may be sufficient without producing adverse effects.
TCS
Wet wrap dressings involve wrapping damp ______ gauze over the affected skin, underneath a layer of dry gauze, usually overnight.
Wet wrap dressings involve wrapping damp ______ gauze over the affected skin, underneath a layer of dry gauze, usually overnight.
The lowest effective ______ of TCS should be used to avoid irreversible atrophy of the skin.
The lowest effective ______ of TCS should be used to avoid irreversible atrophy of the skin.
Long-term control of AD can be maintained with twice-weekly use of the ______ or Topical Calcineurin Inhibitors (TCI) to areas previously affected even if they appear normal.
Long-term control of AD can be maintained with twice-weekly use of the ______ or Topical Calcineurin Inhibitors (TCI) to areas previously affected even if they appear normal.
Epidermal barrier failure is thought to be a main driving force behind subsequent proinflammatory ______ in AD
Epidermal barrier failure is thought to be a main driving force behind subsequent proinflammatory ______ in AD
Moisturizers are a daily part of skin care in atopic dermatitis and patients often use a variety of products based on ______, skin type, season, and disease state
Moisturizers are a daily part of skin care in atopic dermatitis and patients often use a variety of products based on ______, skin type, season, and disease state
Regular ______ use has been demonstrated to have a steroid-sparing benefit in managing atopic dermatitis
Regular ______ use has been demonstrated to have a steroid-sparing benefit in managing atopic dermatitis
Therapy with systemic ______ and anxiolytics are effective through their soporific effects used in the evening
Therapy with systemic ______ and anxiolytics are effective through their soporific effects used in the evening
Ceramides, hyaluronic acid, dimethicone, licorice extract (glycyrrhetinic acid), and ______ are ingredients in prescription “barrier repair creams”
Ceramides, hyaluronic acid, dimethicone, licorice extract (glycyrrhetinic acid), and ______ are ingredients in prescription “barrier repair creams”
Relieving the ______ of AD is crucial in preventing the itch-scratching cycle of this disorder
Relieving the ______ of AD is crucial in preventing the itch-scratching cycle of this disorder
Calcineurin inhibitors prevent T-cell ______, inhibit inflammatory cytokine release and down-regulate high affinity IgE receptor expression on Langerhans cells.
Calcineurin inhibitors prevent T-cell ______, inhibit inflammatory cytokine release and down-regulate high affinity IgE receptor expression on Langerhans cells.
Topical ______ (ProtopicTM) and pimecrolimus (ElidelTM) have been approved for the treatment of AD in the United States and Europe.
Topical ______ (ProtopicTM) and pimecrolimus (ElidelTM) have been approved for the treatment of AD in the United States and Europe.
The most common adverse side effect of crisaborole ointment (EucrisaTM) consists of ______ at the site of application.
The most common adverse side effect of crisaborole ointment (EucrisaTM) consists of ______ at the site of application.
Crisaborole ointment (EucrisaTM) came on the market at the end of 2016 for children over 2 years of age and adults with ______ to moderate AD.
Crisaborole ointment (EucrisaTM) came on the market at the end of 2016 for children over 2 years of age and adults with ______ to moderate AD.
Crisaborole ointment (EucrisaTM) works by inhibiting ______-4 (PDE-4), preventing breakdown of cyclic AMP (cAMP).
Crisaborole ointment (EucrisaTM) works by inhibiting ______-4 (PDE-4), preventing breakdown of cyclic AMP (cAMP).
Crisaborole ointment (EucrisaTM) ultimately leads to an increase in ______ cytokines.
Crisaborole ointment (EucrisaTM) ultimately leads to an increase in ______ cytokines.
